Reversibility of PRKAG2 Glycogen-Storage Cardiomyopathy and Electrophysiological Manifestations
- 15 January 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 117 (2), 144-154
- https://doi.org/10.1161/circulationaha.107.726752
Abstract
Background— PRKAG2 mutations cause glycogen-storage cardiomyopathy, ventricular preexcitation, and conduction system degeneration. A genetic approach that utilizes a binary inducible transgenic system was used to investigate the disease mechanism and to assess preventability and reversibility of disease features in a mouse model of glycogen-storage cardiomyopathy. Methods and Results— Transgenic (Tg) mice expressing a human N488I PRKAG2 cDNA under control of the tetracycline-repressible α-myosin heavy chain promoter underwent echocardiography, ECG, and in vivo electrophysiology studies. Transgene suppression by tetracycline administration caused a reduction in cardiac glycogen content and was initiated either prenatally (Tg OFF(E-8 weeks) ) or at different time points during life (Tg OFF(4–16 weeks) , Tg OFF(8–20 weeks) , and Tg OFF(>20 weeks) ). One group never received tetracycline, expressing transgene throughout life (Tg ON ). Tg ON mice developed cardiac hypertrophy followed by dilatation, ventricular preexcitation involving multiple accessory pathways, and conduction system disease, including sinus and atrioventricular node dysfunction. Conclusions— Using an externally modifiable transgenic system, cardiomyopathy, cardiac dysfunction, and electrophysiological disorders were demonstrated to be reversible processes in PRKAG2 disease. Transgene suppression during early postnatal development prevented the development of accessory electrical pathways but not cardiomyopathy or conduction system degeneration. Taken together, these data provide insight into mechanisms of cardiac PRKAG2 disease and suggest that glycogen-storage cardiomyopathy can be modulated by lowering glycogen content in the heart.This publication has 43 references indexed in Scilit:
- Transgenesis and cardiac energetics: new insights into cardiac metabolismJournal of Molecular and Cellular Cardiology, 2004
- Cytoarchitecture and intercalated disks of the working myocardium and the conduction system in the mammalian heartThe Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 2004
- Molecular Genetic Analysis of PRKAG2 in Sporadic Wolff‐Parkinson‐White SyndromeJournal of Cardiovascular Electrophysiology, 2003
- Regulation of Channel Gating by AMP-activated Protein Kinase Modulates Cystic Fibrosis Transmembrane Conductance Regulator Activity in Lung Submucosal CellsOnline Journal of Public Health Informatics, 2003
- NORMAL AND ABNORMAL CONSEQUENCES OF APOPTOSIS IN THE HUMAN HEARTAnnual Review of Physiology, 1998
- Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice.JCI Insight, 1997
- Anin vivo analysis of transcriptional elements in the mouse α-myosin heavy chain gene promoterTransgenic Research, 1995
- Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3.JCI Insight, 1995
- Familial Occurrence of Accessory Atrioventricular Pathways (Preexcitation Syndrome)The New England Journal of Medicine, 1987
- Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndromeAmerican Heart Journal, 1978